Nicholas M Clayton Selected Research

sodium 6- ((5- chloro- 2- (((4- chloro- 2- fluorophenyl)methyl)oxy)phenyl)methyl)- 2- pyridinecarboxylate

5/2009

Discovery of sodium 6-[(5-chloro-2-{[(4-chloro-2-fluorophenyl)methyl]oxy}phenyl)methyl]-2-pyridinecarboxylate (GSK269984A) an EP(1) receptor antagonist for the treatment of inflammatory pain.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Nicholas M Clayton Research Topics

Disease

4	Pain (Aches) 01/2018 - 01/2007

Drug/Important Bio-Agent (IBA)

2	6- (2- (5- chloro- 2- (((2,4- difluorophenyl)methyl)oxy)phenyl)- 1- cyclopenten- 1- yl)- 2- pyridinecarboxylic acidIBA 05/2009 - 01/2007
1	GSK726701AIBA 01/2018
1	LigandsIBA 01/2018
1	Acetic Acid (Vinegar)FDA LinkGeneric 01/2018
1	SodiumIBA 05/2009
1	sodium 6- ((5- chloro- 2- (((4- chloro- 2- fluorophenyl)methyl)oxy)phenyl)methyl)- 2- pyridinecarboxylateIBA 05/2009
1	Analgesics (Analgesic Drugs)IBA 01/2009
1	GSK345931AIBA 01/2009
1	ProstaglandinsIBA 01/2007
1	AcidsIBA 01/2007